ILMN Illumina Inc.

The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Illumina, Inc. Investors and Encourages Investors to Contact the Firm

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN) securities between July 26, 2016 and October 10, 2016, inclusive (the “Class Period”). Illumina investors have until February 14, 2017 to file a lead plaintiff motion.

Investors suffering losses on their Illumina investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

The filed complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and failed to disclose: (1) that the Company was experiencing a large decline in high throughput sequencing instrument sales; (2) that the decline was negatively impacting the Company’s revenue; (3) that the Company lacked visibility into trends that could have a substantial impact on the Company’s financial results; (4) that, as such, the Company’s revenue guidance was unreliable and overstated; and (5) that, as a result of the foregoing, Defendants’ positive statements about Illumina’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

On October 10, 2016 Illumina issued a press release announcing disappointing financial results for the third quarter of fiscal year 2016. Illumina had previously forecasted revenues of $625 to $630 million for the quarter, but citing “declining demand for its high-speed genetic sequences”, the Company only generated $607 million.

On this news, shares of Illumina were down as much as 25% during intraday trading on October 11, 2016.

If you purchased shares of Illumina during the Class Period you may move the Court no later than February 14, 2017 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
20/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Illumina Inc.

Illumina, Inc.: Update to credit analysis

Our credit view of this issuer reflects its modest financial leverage, offset by US policies around research funding and tariffs.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Illumina, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 6 March 2026 in which we reassessed the appropriateness of the ratings in the context of the...

Illumina Inc: 1 director

A director at Illumina Inc sold 2,370 shares at 116.180USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Moody's Ratings assigns Baa3 rating to Illumina's senior notes; outloo...

Moody's Ratings (Moody's) assigned a Baa3 rating to the senior unsecured notes offering of Illumina, Inc. (Illumina). There are no changes to Illumina's existing ratings including the Baa3 senior unsecured notes, Baa3 issuer rating and (P)Baa3 senior unsecured shelf registration. The outlook is unch...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch